• Necrostatin 2 (Nec-2): Reframing Necroptosis Inhibition in I

  2026-06-17

  Explore how Necrostatin 2 (Nec-2) enables precise RIPK2-targeted necroptosis inhibition and advances our understanding of programmed necrotic cell death in inflammatory models. This article uniquely bridges membrane repair, immune regulation, and practical assay design.

• GIGYF2 Drives Hepatic Insulin Resistance via STAU1/PTEN Axis

  2026-06-17

  Lv et al. identify the RNA-binding protein GIGYF2 as a central regulator of hepatic insulin resistance, acting via STAU1-mediated stabilization of PTEN mRNA and disruption of PI3K/AKT signaling. Their integrative cellular and animal models highlight GIGYF2 as a potential target for metabolic disease intervention.

• Alpha-2 Receptor’s Role in Itch and Pain Modulation via Nora

  2026-06-16

  This study reveals that descending noradrenergic projections from the locus coeruleus modulate itch and pain antagonistically through spinal α2 receptors. Using chemogenetic and pharmacological approaches, the authors delineate a pathway that explains how pain and itch are centrally balanced, with implications for future therapeutic targets in sensory modulation.

• PAD4-IN-2 TFA: Targeted Tumor Immunomodulation Beyond NET In

  2026-06-16

  Discover how PAD4-IN-2 TFA, a meta-phenylboronic acid-modified PAD4 inhibitor, uniquely modulates the tumor immune microenvironment and inhibits histone H3 citrullination. Explore its advanced mechanistic insights and safe, tumor-selective potential for cancer research.

• Applied Workflows for Everolimus (RAD001) in Cancer Research

  2026-06-15

  Everolimus (RAD001) is a benchmark mTOR inhibitor that empowers translational researchers to dissect cancer cell proliferation and apoptosis. This guide unpacks experimental workflows, protocol enhancements, and troubleshooting strategies for maximizing data quality and reproducibility in mTOR pathway studies.

• CLK2 Inhibition Reverses Platinum Resistance in Ovarian Canc

  2026-06-15

  This study identifies Cdc2-like kinase 2 (CLK2) as a driver of platinum resistance in ovarian cancer, demonstrating that CLK2-mediated phosphorylation of BRCA1 enhances DNA repair and tumor survival. Targeting CLK2 offers a mechanistically supported strategy for overcoming chemoresistance, with implications for alternative splicing and translational oncology research.

• CLK2 Inhibition to Overcome Platinum Resistance in Ovarian C

  2026-06-14

  This study reveals that Cdc2-like kinase 2 (CLK2) upregulation drives platinum resistance in ovarian cancer by enhancing BRCA1-mediated DNA repair. Targeting CLK2 represents a promising strategy for alternative splicing modulation and overcoming chemoresistance, informing new directions in experimental and translational oncology.

• Rhodamine B: Precision Tracing and Quantification Beyond Ima

  2026-06-13

  Explore how Rhodamine B, a versatile fluorescent dye, is revolutionizing quantitative tracer applications in environmental and agricultural research. Discover new protocol insights and critical assay considerations distinct from standard cell labeling uses.

• Strategic Use of TBST in Translational Immunoassays

  2026-06-12

  This thought-leadership article explores the mechanistic, experimental, and strategic dimensions of TBST (Tris-Buffered Saline and Tween 20) in the context of advanced immunoassays. Drawing on recent evidence from metastatic breast cancer research, it offers translational investigators actionable guidance on leveraging TBST to maximize signal fidelity, minimize background, and accelerate reproducible discovery. The piece distinguishes itself by integrating mechanistic insight, rigorous protocol recommendations, and a forward-looking vision for antibody-based workflows.

• Mastering Protein Stability in Plant Extracts: Strategic Ins

  2026-06-12

  This article delivers a nuanced, evidence-driven roadmap for translational plant researchers, unraveling the mechanistic landscape of protease inhibition, benchmarking the APExBIO Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO), and bridging metabolic signaling with protein stability. Integrating mechanistic findings from recent immunometabolic research, this piece empowers advanced workflows for high-fidelity plant protein studies.

• PYR-41 and the New Frontier in Ubiquitin-Proteasome Modulati

  2026-06-11

  This article explores how PYR-41, a potent inhibitor of Ubiquitin-Activating Enzyme E1, is transforming translational research in disease modeling, antiviral immunity, and inflammation. By integrating mechanistic insights from recent viral immunology studies and contextualizing them within the broader competitive landscape, we provide actionable guidance for investigators seeking to leverage ubiquitin-proteasome system inhibition for innovative biological discovery.

• Carboplatin Resistance in TNBC: Mechanisms and Translational

  2026-06-11

  This thought-leadership article explores the mechanistic basis of carboplatin resistance in triple-negative breast cancer (TNBC), focusing on the IGF2BP3–FZD1/7–β-catenin axis and its impact on cancer stem-like cells. By integrating recent high-impact findings with strategic guidance, it offers translational researchers actionable insights for improving chemotherapeutic efficacy and overcoming stemness-driven resistance.

• Anlotinib Hydrochloride: Translating Multi-Target TKI Scienc

  2026-06-10

  Explore how Anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor, is driving innovation in angiogenesis and cancer research. This in-depth analysis reveals mechanistic insights, unique pharmacological features, and practical protocol guidance not found in standard workflows.

• Cucurbitacin I (JSI-124): Applied STAT3 Inhibition in Cancer

  2026-06-10

  Cucurbitacin I (JSI-124) delivers selective STAT3 pathway inhibition, empowering researchers to dissect cancer cell proliferation, invasion, and therapy sensitization. This article translates advanced workflows, troubleshooting insights, and cross-domain innovations into actionable protocols for high-impact oncology research.

• TG003 Cdc2-like Kinase Inhibitor: Protocols for Splicing & C

  2026-06-09

  TG003 enables precise, reproducible modulation of alternative splicing in both basic and translational research—now proven pivotal in platinum-resistant ovarian cancer models. This guide unpacks stepwise protocols, troubleshooting, and advanced workflow tips to maximize TG003's impact on splice site selection research and exon-skipping therapies.

14924 records 1/995 page Next 12345 下5页 Last page